Gillian Mcgovern

Factors such as age, race, marital status, years since diagnosis, and out-of-pocket costs show significance as predictors of quality of life.

Clinical trial analysis results studying VAD-44 in patients with hereditary hemorrhagic telangiectasia (HTT) will be presented at the 2024 American Society of Hematology Annual Meeting & Exposition.

Policies that focus on earlier diagnosis, treatment initiation, and expanded access to treatment can further improve treatment and health equity impacts.

If patterns and trends were to continue, the authors predict that nationwide overweight and obesity prevalence in adults will surpass 80% by 2050.

The indication is for adults with previously treated unresectable or metastatic HER2+ (IHC+) biliary tract cancer (BTC) as detected by an FDA-approved test.

The supplemental new drug application (sNDA) is based on results from a phase 3 trial that enrolled patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Women aged 40 to 44 years at the time of natural menopause showed about a 30% decreased risk for asthma incidence.

If approved, RAG-21 can offer improved outcomes in patients with amyotrophic lateral sclerosis (ALS), particularly those with aggressive subtypes.

Sepsis is the most common cause of hospital-associated death, with mortality rates between 24% and 35% at 30 days.

The guidelines were expanded to include the growing use of genetic testing within cancer prevention, screening, and treatment.